Targeted therapy with kinase inhibitors in aggressive endocrine tumors

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 9, 2013, Pages 1187-1203

  Marotta, Vincenzo ^a   Franzese, Maria Domenica ^a   Del Prete, Michela ^a   Chiofalo, Maria Grazia ^b   Ramundo, Valeria ^a   Esposito, Raffaella ^a   Marciello, Francesca ^a   Pezzullo, Luciano ^b   Carratù, Annachiara ^a   Vitale, Mario ^c   Colao, Annamaria ^a   Faggiano, Antongiulio ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

Cancer therapy; Endocrine tumors; Kinase inhibitors; Protein kinases

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ANTINEOPLASTIC AGENT; AXITINIB; CABOZANTINIB; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DACARBAZINE; EVEROLIMUS; IMATINIB; IODINE 131; LENVATINIB; MOTESANIB; OCTREOTIDE; PACLITAXEL; PAZOPANIB; PLACEBO; PROTEIN KINASE INHIBITOR; SOMATOSTATIN DERIVATIVE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIPIFARNIB; VANDETANIB; VEMURAFENIB; VINCRISTINE;

ABDOMINAL PAIN; ADRENAL CORTEX CARCINOMA; ALOPECIA; AMINO ACID SUBSTITUTION; ANAPLASTIC THYROID CANCER; ANGINA PECTORIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTERIAL THROMBOEMBOLISM; BLEEDING; BLOATING; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; DIARRHEA; DIFFERENTIATED THYROID CANCER; DISEASE PREDISPOSITION; DISTANT METASTASIS; DRUG EFFICACY; DYSPEPSIA; ENDOCRINE TUMOR; FATIGUE; GENE MUTATION; HAIR DISEASE; HAIR HYPOPIGMENTATION; HAIR LOSS; HAND FOOT SYNDROME; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOPHYSIS TUMOR; HYPOPIGMENTATION; HYPOTHYROIDISM; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MALABSORPTION; MAXIMUM TOLERATED DOSE; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PARAGANGLIOMA; PARATHYROID CARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHEOCHROMOCYTOMA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QT PROLONGATION; RASH; REVIEW; SKIN CANCER; STOMATITIS; SUBARACHNOID HEMORRHAGE; THYROID MEDULLARY CARCINOMA; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME; VENOUS THROMBOEMBOLISM; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; PROTEIN KINASE INHIBITORS;

EID: 84877905276     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.796931     Document Type: Review

References (175)

1. Johnson LN. Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys 2009;42(1):1-40
2. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408(3):297-315
3. Johnson LN, Lewis RJ. Structural basis for control by phosphorylation. Chem Rev 2001;101(8):2209-42
4. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010;141(7):1117-34
5. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773(8):1263-84
6. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2(7):489-501
7. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 1996;15(2):165-76
8. Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995;129(4):895-8
9. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1(1):27-31
10. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446(7132):153-8
11. Yu GP, Li JC, Branovan D, et al. Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups. Thyroid 2010;20(5):465-73
12. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011;7(10):569-80
13. Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 2004;183(2):249-56
14. Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 2009;27(18):2977-82
15. Guerra A, Fugazzola L, Marotta V, et al. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab 2012;97(7):2333-40
16. Marotta V, Guerra A, Zatelli MC, et al. BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present. Clin Endocrinol (Oxf) 2013; Epub ahead of print
17. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2(7):851-6
18. Elisei R, Romei C, Cosci B, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 2007;92(12):4725-9
19. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008;93(3):682-7
20. Moura MM, Cavaco BM, Pinto AE, et al. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 2011;96(5):E863-8
21. Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16(4):525-37
22. Peterson RT, Beal PA, Comb MJ, et al. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem 2000;275(10):7416-23
23. Strimpakos AS, Karapanagiotou EM, Saif MW, et al. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 2009;35(2):148-59
24. Shida T, Kishimoto T, Furuya M, et al. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother Pharmacol 2010;65(5):889-93
25. Righi L, Volante M, Rapa I, et al. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer 2010;17(4):977-87
26. von Wichert G, Jehle PM, Hoeflich A, et al. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000;60(16):4573-81
27. Ragazzon B, Assie G, Bertherat J. Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments. Endocr Relat Cancer 2011;18(2):R15-27
28. De Martino MC, van Koetsveld PM, Pivonello R, et al. Role of the mTOR pathway in normal and tumoral adrenal cells. Neuroendocrinology 2010;92(Suppl 1):28-34
29. Jensen RT, Berna MJ, Bingham DB, et al. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008;113(7 Suppl):1807-43
30. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338(5):297-306
31. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91(1):313-19
32. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008;93(10):3943-9
33. Husain M, Alsever RN, Lock JP, et al. Failure of medullary carcinoma of the thyroid to respond to doxorubicin therapy. Horm Res 1978;9(1):22-5
34. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009;16(1):17-44
35. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359(1):31-42
36. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26(29):4708-13
37. Marotta V, Sapio MR, Guerra A, et al. BRAF mutation in cytology samples as a diagnostic tool for papillary thyroid carcinoma. Expert Opin Med Diagn 2011;5(4):277-90
38. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28(7):742-62
39. Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012;118(7):1764-73
40. Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 2011;165(2):315-22
41. Capdevila J, Iglesias L, Halperin I, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 2012;
42. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26(29):4714-19
43. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27(10):1675-84
44. Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. Clin Endocrinol Metab 2010;95(6):2588-95
45. Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161(6):923-31
46. Marotta V, Ramundo V, Camera L, et al. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin Endocrinol (Oxf) 2012;
47. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16(21):5260-8
48. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11(10):962-72
49. Ikuta K, Yano S, Trung VT, et al. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res 2009;15(23):7229-37
50. Sherman SI JB, Cabanillas ME, Licitra LF, et al. A phase II trial of the multi-targeted kinase inhibitor, Lenvatinib (E7080), in advanced radioiodine-refractory differentiated thyroid cancer (DTC). J Clin Oncol (Meeting Abstracts) 2011;29:5503
51. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379(9829):1893-901
52. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366(8):707-14
53. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167-214
54. Perri F, Lorenzo GD, Scarpati GD, et al. Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol 2011;2(3):150-7
55. Cohen MS, Hussain HB, Moley JF. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 2002;132(6):960-6; discussion 66-7
56. Frank-Raue K, Fabel M, Delorme S, et al. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 2007;157(2):215-20
57. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007;92(9):3466-9
58. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27(23):3794-801
59. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28(14):2323-30
60. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62(24):7284-90
61. Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28(5):767-72
62. Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95(6):2664-71
63. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30(2):134-41
64. Papotti M, Olivero M, Volante M, et al. Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol 2000;11(1):19-30
65. Costantini F. Genetic controls and cellular behaviors in branching morphogenesis of the renal collecting system. Wiley Interdiscip Rev Dev Biol 2012;1(5):693-713
66. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29(19):2660-6
67. Schoffski P ER, Müller S, Brose MS, Schlumberger M and EXAM Study Group. An international, double-blind, randomized, placebo-controlled Phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol (Meeting Abstracts) 2012;30:5508
68. Faggiano A, Ramundo V, Dicitore A, et al. Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. J Cell Mol Med 2012;16(7):1563-72
69. Druce M, Chung TT, Grozinsky-Glasberg S, et al. Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2012;77(1):154-5
70. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9(1):61-72
71. Oberg K. Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment. Curr Opin Oncol 2005;17(4):386-91
72. Faggiano A, Ferolla P, Grimaldi F, et al. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: THE NET MANAGEMENT STUDY. J Endocrinol Invest 2011;
73. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97(4):934-59
74. Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995;169(1):36-42; discussion 42-3
75. Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998;32(2):133-8
76. Chaudhry A, Papanicolaou V, Oberg K, et al. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res 1992;52(4):1006-12
77. Koch CA, Gimm O, Vortmeyer AO, et al. Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy? Ann N Y Acad Sci 2006;1073:517-26
78. Fjallskog ML, Hessman O, Eriksson B, et al. Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol 2007;46(6):741-6
79. Hansel DE, Rahman A, Hermans J, et al. Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol 2003;16(7):652-9
80. La Rosa S, Uccella S, Finzi G, et al. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 2003;34(1):18-27
81. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is anti-angiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23(5):939-52
82. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26(20):3403-10
83. Ansell SM, Pitot HC, Burch PA, et al. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 2001;91(8):1543-8
84. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24(3):401-6
85. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):501-13
86. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26(26):4311-18
87. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28(1):69-76
88. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):514-23
89. Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009;360(2):195-7
90. Bourcier ME, Sherrod A, DiGuardo M, et al. Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. J Clin Endocrinol Metab 2009;94(9):3157-62
91. Ong GS, Henley DE, Hurley D, et al. Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Eur J Endocrinol 2010;162(5):1001-8
92. Oberstein PE, Saif MW. Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting"; 3-7 June 2011; Chicago, IL, USA. JOP 2011;12(4):358-61
93. Eisenhofer G, Bornstein SR, Brouwers FM, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 2004;11(3):423-36
94. Huang H, Abraham J, Hung E, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 2008;113(8):2020-8
95. Sisson JC. Radiopharmaceutical treatment of pheochromocytomas. Ann N Y Acad Sci 2002;970:54-60
96. Ramundo V, Ercolino T, Faggiano A, et al. Genetic-clinical profile of subjects with apparently sporadic extra-adrenal paragangliomas. Front Endocrinol (Lausanne) 2012;3:65
97. Lisztwan J, Imbert G, Wirbelauer C, et al. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 1999;13(14):1822-33
98. Pollard PJ, El-Bahrawy M, Poulsom R, et al. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab 2006;91(11):4593-8
99. Salmenkivi K, Heikkila P, Liu J, et al. VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS 2003;111(4):458-64
100. Joshua AM, Ezzat S, Asa SL, et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 2009;94(1):5-9
101. Jimenez C, Cabanillas ME, Santarpia L, et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 2009;94(2):386-91
102. Hahn NM, Reckova M, Cheng L, et al. Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol 2009;27(3):460-3
103. Park KS, Lee JL, Ahn H, et al. Sunitinib, a novel therapy for anthracycline-and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol 2009;39(5):327-31
104. Gross DJ, Munter G, Bitan M, et al. The role of imatinib mesylate (Gleevec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006;13(2):535-40
105. Druce MR, Kaltsas GA, Fraenkel M, et al. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res 2009;41(9):697-702
106. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5):277-300
107. Gicquel C, Bertagna X, Gaston V, et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 2001;61(18):6762-7
108. de Reynies A, Assie G, Rickman DS, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 2009;27(7):1108-15
109. Barlaskar FM, Spalding AC, Heaton JH, et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 2009;94(1):204-12
110. Tacon LJ, Prichard RS, Soon PS, et al. Current and emerging therapies for advanced adrenocortical carcinoma. Oncologist 2011;16(1):36-48
111. Giordano TJ. Adrenocortical tumors: an integrated clinical, pathologic, and molecular approach at the University of Michigan. Arch Pathol Lab Med 2010;134(10):1440-3
112. Doghman M, El Wakil A, Cardinaud B, et al. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res 2010;70(11):4666-75
113. Naing A, Kurzrock R, Burger A, et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res 2011;17(18):6052-60
114. Lee JO, Lee KW, Kim CJ, et al. Metastatic adrenocortical carcinoma treated with sunitinib: a case report. Jpn J Clin Oncol 2009;39(3):183-5
115. Fassnacht M, Kreissl MC, Weismann D, et al. New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 2009;123(1):117-41
116. Hong DS, Sebti SM, Newman RA, et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 2009;15(22):7061-8
117. Butler C, Butler WM, Rizvi AA. Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. Endocr Pract 2010;16(3):441-5
118. Berruti A, Sperone P, Ferrero A, et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol 2012;166(3):451-8
119. Buchfelder M. Management of aggressive pituitary adenomas: current treatment strategies. Pituitary 2009;12(3):256-60
120. Kaltsas GA, Nomikos P, Kontogeorgos G, et al. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005;90(5):3089-99
121. Ortiz LD, Syro LV, Scheithauer BW, et al. Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo) 2012;67(Suppl 1):119-23
122. Dworakowska D, Wlodek E, Leontiou CA, et al. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer 2009;16(4):1329-38
123. Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005;132(3):359-72
124. Schulte KM, Talat N. Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol 2012;8(10):612-22
125. Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 2007;109(9):1736-41
126. Hundahl SA, Fleming ID, Fremgen AM, et al. Two hundred eighty-six cases of parathyroid carcinoma treated in the U. S. between 1985 and 1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1999;86(3):538-44
127. Calandra DB, Chejfec G, Foy BK, et al. Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery 1984;96(6):1132-7
128. Bukowski RM, Sheeler L, Cunningham J, et al. Successful combination chemotherapy for metastatic parathyroid carcinoma. Arch Intern Med 1984;144(2):399-400
129. Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 2003;40(9):657-63
130. Shattuck TM, Valimaki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003;349(18):1722-9
131. Crean S, Boyd DM, Sercus B, et al. Safety of multi-targeted kinase inhibitors as monotherapy treatment of cancer: a systematic review of the literature. Curr Drug Saf 2009;4(2):143-54
132. McNeil C. Two targets, one drug for new EGFR inhibitors. J Natl Cancer Inst 2006;98(16):1102-3
133. Cabanillas ME, Hu MI, Durand JB, et al. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011;2011:985780
134. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7(5):332-44
135. Schmidinger M, Arnold D, Szczylik C, et al. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest 2010;28(8):856-64
136. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006;24(9):1363-9
137. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010;102(9):596-604
138. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26(32):5204-12
139. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370(9604):2011-19
140. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007;25(22):3362-71
141. Zangari M, Fink LM, Elice F, et al. Thrombotic events in patients with cancer receiving anti-angiogenesis agents. J Clin Oncol 2009;27(29):4865-73
142. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96(12):1788-95
143. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003;21(18):3542; author reply 43
144. Peters NA, Richel DJ, Verhoeff JJ, et al. Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol 2008;26(14):2405-6
145. Basille D, Andrejak M, Bentayeb H, et al. Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy. Ann Pharmacother 2010;44(2):383-6
146. Elice F, Jacoub J, Rickles FR, et al. Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol 2008;83(11):862-70
147. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26(4):650-6
148. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009;10(10):967-74
149. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral anti-angiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23(24):5474-83
150. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
151. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
152. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90
153. Maklad A, Nicolai JR, Bichsel KJ, et al. The EGFR is required for proper innervation to the skin. J Invest Dermatol 2009;129(3):690-8
154. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009;4(2):107-19
155. Daimon M, Kato T, Kaino W, et al. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Jpn J Clin Oncol 2012;42(8):742-7
156. Clemons J, Gao D, Naam M, et al. Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib. Clin Genitourin Cancer 2012
157. Hammond-Thelin LA. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics. Dermatol Clin 2008;26(1):121-59, ix
158. Lynch TJ Jr, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007;12(5):610-21
159. Ray DW, Ren SG, Melmed S. Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. J Clin Invest 1996;97(8):1852-9
160. Bilgir O, Kebapcilar L, Bilgir F, et al. Is there any relationship between imatinib mesylate medication and hypothalamic-pituitary-adrenal axis dysfunction? Int J Clin Pract 2010;64(1):45-50
161. Yoon SJ, Kim KH, Chung HM, et al. Gene expression profiling of early follicular development in primordial, primary, and secondary follicles. Fertil Steril 2006;85(1):193-203
162. Christopoulos C, Dimakopoulou V, Rotas E. Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med 2008;358(10):1079-80
163. Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 2003;40(2 Suppl 2):21-5
164. Schultheis B, Nijmeijer BA, Yin H, et al. Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leuk Res 2012;36(3):271-4
165. Costa DB, Huberman MS. Improvement of type 2 diabetes in a lung cancer patient treated with erlotinib. Diabetes Care 2006;29(7):1711
166. Tsapas A, Vlachaki E, Sarigianni M, et al. Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML). Leuk Res 2008;32(4):674-5
167. Breccia M, Muscaritoli M, Cannella L, et al. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res 2008;32(10):1626-8
168. Templeton A, Brandle M, Cerny T, et al. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol 2008;19(4):824-5
169. Agostino NM, Chinchilli VM, Lynch CJ, et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 2011;17(3):197-202
170. Campbell M, Allen WE, Silversides JA, et al. Glucose-induced phosphatidylinositol 3-kinase and mitogen-activated protein kinase-dependent upregulation of the platelet-derived growth factor-beta receptor potentiates vascular smooth muscle cell chemotaxis. Diabetes 2003;52(2):519-26
171. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 2006;533(1-3):327-40
172. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603
173. Zimmermann K, Schmittel A, Steiner U, et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009;76(5):350-4
174. Vainas I, Koussis C, Pazaitou-Panayiotou K, et al. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma. J Exp Clin Cancer Res 2004;23(4):549-59
175. Naraev BG, Strosberg JR, Halfdanarson TR. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology 2012;83(3):117-27